<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> characterised by a heterogenous group of antibodies directed against negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> including <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), anticardiolipin antibodies (aCL) and β-2 glycoprotein I (aβ-2-GP1) </plain></SENT>
<SENT sid="1" pm="."><plain>The major features of this disorder include arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and recurrent fetal loss </plain></SENT>
<SENT sid="2" pm="."><plain>The vasculature of the eye is frequently involved and may be the presenting manifestation </plain></SENT>
<SENT sid="3" pm="."><plain>A diagnosis of APS should be considered in a young patients without traditional thromboembolic risk factors presenting with ocular <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">vaso-occlusive disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Management of these patients involves a team-approach with a haematologist/oncologist or rheumatologist to manage the coagulation status of these patients to prevent further systemic <z:e sem="disease" ids="C1096458" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">vascular occlusions</z:e> </plain></SENT>
</text></document>